Posts

Posted on

Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET.

Webcast Information

Please register for the event on the Events and Presentations page of Disc’s website at https://ir.discmedicine.com. A replay of the webcast will be made available on the website following the call.

About Bitopertin

Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is developing bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, an open-label extension HELIOS trial, and the Phase 3 double-blind, placebo-controlled APOLLO trial.

Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
[email protected]

Investor Relations Contact

Kevin Lui
Precision AQ
[email protected]



Posted on

Evercore Appoints Nigel Dawn and Naveen Nataraj as Co-Presidents

Evercore Appoints Nigel Dawn and Naveen Nataraj as Co-Presidents

Co-President roles will add senior leadership depth as Evercore advances its strategic priorities

NEW YORK–(BUSINESS WIRE)–
Evercore (NYSE: EVR) today announced that its Board of Directors has appointed Nigel Dawn and Naveen Nataraj as Co-Presidents of the firm, effective January 1, 2027. Mr. Dawn and Mr. Nataraj will report to Chairman and Chief Executive Officer John S. Weinberg, who will continue to lead Evercore, its Management Committee and the firm’s strategic direction. Evercore’s Board and Mr. Weinberg have agreed that he will serve as Chairman and CEO for at least the next three years.

This new leadership structure will enable the firm to continue to build on its strategy for growth. In their new roles, Mr. Dawn and Mr. Nataraj will work closely with Mr. Weinberg, Roger C. Altman, Evercore’s founder and Senior Chairman, and the global senior leadership team to execute the firm’s strategy and drive global expansion. These appointments will strengthen Evercore’s ability to serve clients while preserving the values, culture and commitment to people that have long defined the firm.

Daniel Mendelow will become sole Head of U.S. Investment Banking, with responsibility for Evercore’s largest business. Jason Sobol will become Chairman of U.S. Investment Banking and will collaborate closely with Eduardo Mestre, who will remain Chairman of Global Investment Banking.

John S. Weinberg said, “As Evercore has grown and evolved, we see increased opportunities to bring value for our clients. This leadership structure will help us drive our strategy more effectively while reinforcing our commitment to clients, our values and our culture. Nigel and Naveen are accomplished leaders who will make important contributions in these roles. I am excited to continue working with them and with our global senior leadership.”

Roger C. Altman said, “Evercore is a different firm today, even compared with three years ago. It is much larger, broader and more global, and is competitively stronger. The firm will benefit from additional management resources to support John, and today’s announcement reflects that need. I could not have greater confidence in Nigel and Naveen and look forward to working with them in their new roles. Moreover, John’s leadership, judgment and deep commitment to our people and clients have been, and will continue to be, central to what we are building.”

Mr. Dawn has led the development of the market-leading global Private Capital Advisory (“PCA”) business, with teams in the United States, Europe and Singapore. Mr. Dawn will become Chairman of PCA and remain closely connected to the business and its clients.

During his tenure at Evercore, Mr. Nataraj has advised some of the firm’s most important clients on transactions across a broad range of industries. He will continue to advise clients and remain actively engaged in the firm’s Investment Banking business.

About Evercore

Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic and financial significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings and capital structure. Evercore also assists clients in raising public and private capital, delivers equity research and equity sales and agency trading execution, and provides wealth and investment management services to high-net-worth and institutional investors. Founded in 1995, the firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in the Americas, Europe, the Middle East and Asia. For more information, please visit www.evercore.com.

Media Contact:

Jamie Easton

Head of Communications & External Affairs

[email protected]

Investor Contact:

Katy Haber

Head of Investor Relations & ESG

[email protected]

KEYWORDS: New York Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

INVESTOR DEADLINE: Doximity, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before November 16, 2026 Deadline, RGRD Law Announces – DOCS

SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Doximity, Inc. (NYSE: DOCS) common stock between August 8, 2024 and May 13, 2026, both dates inclusive (the “Class Period”), have until Monday, November 16, 2026 to seek appointment as lead plaintiff of the Doximity class action lawsuit. Captioned Michigan Laborers’ Pension Fund v. Doximity, Inc., No. 26-cv-10529 (N.D. Cal.), the Doximity class action lawsuit charges Doximity and certain of Doximity’s top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Doximity

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-doximity-class-action-lawsuit-docs.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert

of Robbins Geller by calling 800/851-7783 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: Doximity operates a digital platform for medical professionals.

The Doximity class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Doximity overstated the impact that its Newsfeed would have on its revenue growth; and (ii) Doximity was losing market share to its competitors with more favorable pricing and engagement models, while also using banner ads and e-newsletters instead of deep engagement tactics.

On November 6, 2025, Doximity allegedly reported second quarter results where they expressed a degree of caution regarding the outlook for ad spending and implied a slowdown in sales growth in the second half of the 2026 fiscal year. On this news, the price of Doximity common stock dropped 13%, according to the complaint.

The complaint further alleges that on February 5, 2026, Doximity lowered its revenue guidance for 2026 full fiscal year, which ended on March 31, 2026, and announced that its sales growth had decelerated while its net income had contracted, which will negatively impact its 2026 fiscal fourth quarter. On this news, the price of Doximity common stock declined 17%, according to the complaint.

Finally, on May 13, 2026, Doximity allegedly announced that it missed its already-reduced revenue guidance and projected a significantly slower pace of growth for its 2027 fiscal year, which ends on March 31, 2027. On this news, the price of Doximity common stock fell 23%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Doximity common stock during the Class Period to seek appointment as lead plaintiff in the Doximity class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Doximity class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Doximity class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Doximity class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
            Robbins Geller Rudman & Dowd LLP
            Ken Dolitsky
            Michael Albert
            655 W. Broadway, Suite 1900, San Diego, CA 92101
            800/851-7783
            [email protected]



Posted on

“Where Are the Numbers?” Doug Bergeron Calls on Ethan Allen to Release First Quarter Results Before November 4 Board Vote

“Where Are the Numbers?” Doug Bergeron Calls on Ethan Allen to Release First Quarter Results Before November 4 Board Vote

Company Has Yet to Announce an Earnings Release Date, Departing from a Decade of Consistent Disclosure Practice

Raises Serious Questions About Board Credibility Following Inaccurate Financial Claims and Mischaracterizations of Mr. Bergeron’s Nominees and Plan to Restore Growth

Warns Shareholders Not to Be Fooled by Selective Financial Claims and Repeated Growth Promises That Obscure Two Decades of Decline

PARK CITY, Utah–(BUSINESS WIRE)–
Doug Bergeron, a significant shareholder of Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) with beneficial ownership, collectively with his affiliates and associates, of approximately 5.2% of Ethan Allen’s outstanding common stock, today called on Ethan Allen to announce when it will release its fiscal first quarter 2027 financial results and to publish those results sufficiently ahead of its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on November 4, 2026.

“Where are the numbers? Shareholders are on the verge of deciding who will oversee Ethan Allen’s next chapter, yet the Board of Directors (the “Board”) has not told them if, or when, they will see the Company’s latest financial results. For each of the past ten years, Ethan Allen announced the release date for its fiscal first quarter results no later than October 18.1 This year, with the Annual Meeting just over two weeks away, shareholders have heard nothing. However, this election is not about a single quarter. After 20 years of deteriorating performance, including four consecutive quarters of fixed-cost deleveraging from declining sales, shareholders should have no reason to trust the Chairman and CEO and the incumbent Board’s promises of sustainable growth.”

Mr. Bergeron also set the record straight on several willfully misleading and inaccurate representations in the Company’s recent investor presentation and proxy materials that further call into question the Board’s record and credibility:

  • Another “positioned for growth” promise without results. In 2015, defending against a proxy contest, the Company told shareholders it was “well positioned to begin an accelerated growth phase.”2 Eleven years later, the business is substantially smaller, less profitable and less valuable. Years of design-center “refreshes,” expanded assortments, increased advertising and digital initiatives have failed to produce sustained growth, and the 12.8% five-year average operating margin the Company highlights obscures a 7.8% margin in FY2026, less than half the 17.3% reached in FY2023.3 Activity is not achievement, and historical averages cannot disguise the deterioration.
  • Returning cash from a shrinking business is not the same as compounding shareholder value. Over five years, Ethan Allen’s share price has appreciated just 2.5%, with approximately 94% of its reported 45% total shareholder return attributable to dividends.4 Over 10 years, the share price has declined 31%, despite a reported total shareholder return of 27%5 – a 58 percentage point swing due to dividends.
  • The greatest risk to Ethan Allen’s dividend is the continued erosion of the earnings base that supports it. The regular dividend consumed approximately 97% of adjusted EPS in FY2026, up from just 29% in FY2022. Cash dividends paid of $46 million exceeded the year’s $41 million of free cash flow, itself down 41% from FY2024.6 Yet, after the proxy contest began, the Board declared another $76 million special dividend. The Board continues distributing capital while failing to rebuild the earnings required to sustain those distributions.
  • The Board that accepted two decades of decline should not be entrusted with selecting and overseeing the next CEO. After 38 years under the same Chairman and CEO, the Board repeatedly extended Mr. Kathwari’s tenure and accepted performance standards that moved down with the business, without imposing meaningful consequences. A formal succession process was announced only after this proxy contest began – 11 days after Mr. Bergeron announced his own independent CEO search – with a successor to be announced by June 2027. Worse, the Board wants the next CEO to “build on and accelerate” the same strategy that has failed to restore growth. Why should the Board that did not hold the current CEO accountable be entrusted to choose, and then oversee, the next one?
  • Mr. Bergeron and his nominees bring the expertise a modern premium home furnishings company demands, and a clear plan to transition leadership responsibly and restore growth. The nominees bring relevant manufacturing, sourcing, merchandising, technology, operating and governance experience, as well as brand and digital capabilities that are noticeably absent from the current Board. An experienced interim CEO would lead the business, supported by existing operating management, while the Board validates strategy, stages investment and establishes accountability. The incumbents offer promise after promise of change yet never deliver. We are offering an actionable plan for change.

“The Board’s October 15 investor presentation only reinforces our concerns about its pattern of selective financial disclosures, misleading representations and lack of accountability. First, the Board selects the numbers it wants shareholders to see. Now, it has not even said when they will see the latest results. Shareholders deserve the full picture, not selective disclosures and more promises from a Board that has allowed the decline to continue under the same Chairman and CEO. On November 4, shareholders have an opportunity to demand a new standard of transparency, accountability and leadership by electing a Board with the experience and a credible plan to restore growth and drive long-term value creation.”

Additional materials related to Mr. Bergeron’s campaign, including video interviews with his five director candidates, may be found at www.EthanAllenGrowth.com. Shareholders are encouraged to follow the campaign’s LinkedIn and X pages to stay informed in real time.

PROTECT YOUR INVESTMENT. RENEW AN AMERICAN ICON. VOTE THE WHITE UNIVERSAL PROXY CARD TODAY

Shareholders with questions on how to vote their shares may visit www.EthanAllenGrowth.com/How-To-Vote.

ADDITIONAL INFORMATION

DGB Investment, Inc. and Douglas G. Bergeron, together with the other participants in their solicitation (collectively, “DGB”), have filed a definitive proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit proxies with respect to the election of DGB’s slate of highly qualified director candidates and the other proposals to be presented at the 2026 annual meeting of stockholders (the “Annual Meeting”) of Ethan Allen Interiors Inc., a Delaware corporation (the “Company”). Stockholders are advised to read the proxy statement and any other documents related to the solicitation of stockholders of the Company in connection with the Annual Meeting because they contain important information, including information relating to the participants in DGB’s proxy solicitation. These materials and other materials filed by DGB with the SEC in connection with the solicitation of proxies are available at no charge on the SEC’s website at http://www.sec.gov. The definitive proxy statement and other relevant documents filed by DGB with the SEC are also available, without charge, by directing a request to DGB’s proxy solicitor, Okapi Partners LLC, at its toll-free number (877) 285-5990 or via email at [email protected].

1 Company SEC filings and press releases announcing the dates of its fiscal first quarter earnings releases for fiscal years 2017 through 2026.

2 Ethan Allen first quarter fiscal 2016 earnings press release dated October 27, 2015.

3 Ethan Allen SEC filings; S&P Capital IQ.

4 As of August 4, 2026, the last trading day before Mr. Bergeron publicly launched his campaign; Ethan Allen SEC filings; S&P Capital IQ.

5 As of August 4, 2026; Ethan Allen SEC filings; S&P Capital IQ.

6 Ethan Allen SEC filings; S&P Capital IQ.

Media Contact:

[email protected]

Investor Contact:

Bruce Goldfarb / Chuck Garske

Okapi Partners

(877) 285-5990

[email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Home Goods Interior Design Retail Department Stores Construction & Property

MEDIA:

Posted on

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against D-Wave Quantum Inc. (NASDAQ: QBTS) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

NEW YORK, Oct. 18, 2026 (GLOBE NEWSWIRE) — Lead Plaintiff Deadline: December 15, 2026. Investors who purchased (NASDAQ: QBTS) securities between February 26, 2026 and August 25, 2026 may be eligible to recover losses.

Bronstein, Gewirtz & Grossman, LLC (“BG&G”), a nationally recognized investor-rights law firm, announces that it has filed a securities class action lawsuit against D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”) and certain of its officers.

The lawsuit, captioned , Case No. 5:26-cv-11953, was filed on October 15, 2026, in the United States District Court for the Northern District of California. The action seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired D-Wave securities between February 26, 2026 and August 25, 2026, both dates inclusive (the “Class Period”), for alleged violations of the federal securities laws.

Investors are encouraged to join this case by visiting the firm’s website: https://bgandg.com/cases/d-wave-quantum-inc-qbts-class_action_lawsuit/

D-Wave Case Details

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and financial prospects. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:  

  (1) Defendants materially overstated D-Wave’s business, operational, and financial prospects;
  (2) The foregoing was reasonably likely to negatively impact the Company’s business and reputation; and
  (3) As a result, Defendants’ public statements were materially false and misleading at all relevant times.

On August 6, 2026, D-Wave reported second-quarter revenue of $3.08 million, falling short of analysts’ expectations of approximately $4.03 million to $4.08 million. On this news, D-Wave’s stock price declined $1.99 per share, or 9.28%, closing at $19.41 per share.

Then, on August 25, 2026, D-Wave announced that Chief Financial Officer John Markovich would retire and resign from his position effective September 2, 2026. On this news, D-Wave’s stock price fell $1.84 per share, or 9.51%, closing at $17.51 per share on August 26, 2026.

What’s Next for D-Wave Investors?

Bronstein, Gewirtz & Grossman, LLC has already filed a class action lawsuit on behalf of D-Wave investors. The action is pending in the United States District Court for the Northern District of California under Case No. 5:26-cv-11953.

If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/d-wave-quantum-inc-qbts-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in D-Wave you have until December 15, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to D-Wave Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for D-Wave Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.



Posted on

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms.

“Despite significant advances in the treatment of IBD, many patients still do not achieve or maintain the level of disease control we would like to see, underscoring the need for new approaches that can deliver deeper and more durable responses,” said Silvio Danese, M.D., Ph.D., Professor of Gastroenterology at Vita-Salute San Raffaele University and Head of the Gastroenterology and Endoscopy Unit at IRCCS San Raffaele Hospital in Milan, and Chair of the SKYLINE trial Steering Committee. “We believe that advanced combination therapy provides a strong probability of enhanced efficacy compared to today’s monotherapies, and Spyre’s approach of combining optimized versions of antibodies against proven targets represents one of the most promising pipelines in the field. With clinical proof-of-concept now demonstrated across SPY001, SPY002 and SPY003, we are increasingly excited to see the combination results next year with the potential to raise the therapeutic ceiling for patients with IBD.”

The poster and presentation will be available for viewing during UEGW, and details are as follows:

Oral Presentation

Title: Efficacy and Safety of Half-Life Extended Antibodies SPY001, SPY002, and SPY003 for Induction Treatment of Moderately to Severely Active Ulcerative Colitis
Abstract Session: Hot Topics in IBD
Presentation Date/Time: Sunday, Oct. 18,15:30-15:40 CEST
Presentation Location: Room B3
Presenter: Silvio Danese, M.D., Ph.D., San Raffaele Hospital

Moderated Poster

Title: Anti-α4β7 integrin, anti-TL1A, and anti-IL-23 are efficacious in TNBS-induced colitis using humanized mice, and combinations further improve efficacy
Poster Session: New Insights into IBD Biology (II)
Session Date/Time: Monday, Oct. 19, 16:06-16:12 CEST
Presentation Location: Hall 7, Poster Stage 2
Presenter: Andy Spencer, Ph.D., Spyre Therapeutics

Full session details can be accessed via the UEGW program.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, visit Spyre’s website at www.spyre.com.

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Spyre’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre’s ability to develop next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential of advanced combination therapy to provide enhanced efficacy compared to today’s monotherapies; the potential of combination therapies to raise the therapeutic ceiling for patients with IBD; and Spyre’s clinical development activities, including the expected timing and results of the ongoing SKYLINE Phase 2 platform trial, including timing of data readouts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would,” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described under the heading “Risk Factors,” “Risk Factor Summary” and “Note about Forward-Looking Statements” in Spyre’s most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or will file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.

For Investors:     
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
[email protected]

For Media:     
Josie Butler, 1AB
[email protected]



Posted on

FOXF Investors with $100,000 in Losses Have Opportunity to Join Fox Factory Holding Corp. Fraud Investigation with SBS Law

FOXF Investors with $100,000 in Losses Have Opportunity to Join Fox Factory Holding Corp. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fox Factory Holding Corp. (“Fox Factory” or “the Company”) (NASDAQ: FOXF) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Fox Factory lowered its sales guidance for FY2026 despite previously affirming the guidance earlier in the year. Based on this news, shares of Fox Factory fell by 13.3% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Gildan Activewear Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – GIL

Gildan Activewear Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – GIL

LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Gildan Activewear Inc. (“Gildan” or “the Company”) (NYSE: GIL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of GIL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 19, 2025 to June 15, 2026

DEADLINE: December 14, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Gildan engaged in channel stuffing. The Company failed to maintain adequate internal controls. Based on these facts, Gildan’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Posted on

D-Wave Quantum Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – QBTS

D-Wave Quantum Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – QBTS

LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against D-Wave Quantum Inc. (“D-Wave” or “the Company”) (NASDAQ: QBTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of QBTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 26, 2026 to August 25, 2026

DEADLINE: December 15, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. D-Wave overstated its business and financial prospects. Based on these facts, D-Wave’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Posted on

NIP Group Inc. Announces Results of Extraordinary General Meeting

ABU DHABI, United Arab Emirates, Oct. 16, 2026 (GLOBE NEWSWIRE) — NIP Group Inc. (“NIP Group” or the “Company”) (NASDAQ: NIPG), a leading digital entertainment company, today announced that the Company’s extraordinary general meeting of shareholders (the “EGM”) was held in Hong Kong on October 16, 2026. During the EGM, the following proposed resolutions were duly passed:

  1. by a special resolution that, subject to the passing of Resolution 2, the Company’s authorized share capital be increased FROM US$200,000 divided into 2,000,000,000 shares comprising (i) 1,756,459,263 Class A ordinary shares of a par value of US$0.0001 each (the “Class A Ordinary Shares”), (ii) 148,331,658 Class B1 ordinary shares of a par value of US$0.0001 each (the “Class B1 Ordinary Shares”) and (iii) 95,209,079 Class B2 ordinary shares of a par value of US$0.0001 each (the “Class B2 Ordinary Shares”), each of such class or classes (however designated) as the Company’s board of directors may determine in accordance with the memorandum and articles of association of the Company then in effect TO US$1,000,000 divided into 10,000,000,000 shares comprising (i) 8,782,296,315 Class A Ordinary Shares, (ii) 741,658,290 Class B1 Ordinary Shares and (iii) 476,045,395 Class B2 Ordinary Shares, each of such class or classes (however designated) as the Company’s board of directors may determine in accordance with the memorandum and articles of association of the Company then in effect, by the creation of (i) 7,025,837,052 Class A Ordinary Shares, (ii) 593,326,632 Class B1 Ordinary Shares, and (iii) 380,836,316 Class B2 Ordinary Shares.
  2. by a special resolution that the Tenth Amended and Restated Memorandum and Articles of Association of the Company currently in effect be amended and restated by the deletion in their entirety and by the substitution in their place of the Eleventh Amended and Restated Memorandum and Articles of Association in the form attached as Exhibit A to the Notice of Extraordinary General Meeting to reflect the proposed amendments set out in the foregoing Resolution 1.
  3. by an ordinary resolution that (i) the Company give, make, sign, execute and deliver all such agreements, letters, notices, certificates, acknowledgements, instructions and other documents (whether of a like nature or not) in relation to the matters contemplated in the foregoing resolutions as may be considered necessary or desirable by any director or officer of the Company for the purpose of the coming into effect of or otherwise giving effect to, consummating or completing or procuring the performance and completion of all or any of the matters described in the foregoing resolutions, and (ii) any one director or officer or the registered office provider of the Company be and is hereby authorized to take any and every action that might be necessary, appropriate, or desirable to give effect to the foregoing resolutions as such director or officer or the registered office provider, in his/her/its absolute discretion, thinks fit, including but not limited to, attendance on any filing or registration procedures for and on behalf of the Company in the Cayman Islands. 

About NIP Group

NIP Group (NASDAQ: NIPG) operates at the nexus of Bitcoin mining, compute infrastructure and global digital entertainment. Rooted in a decade of gaming DNA and industry leadership, the Company brings a cultural and community-driven edge to digital asset operations. Headquartered in Abu Dhabi with teams worldwide, NIP Group pairs significant compute capacity with a global gaming and entertainment ecosystem including esports teams, live events and content networks, reaching hundreds of millions of fans.

Safe Harbor Statements

This press release contains statements that constitute “forward-looking” statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” or other similar expressions. Among other things, the business outlook and quotations from management in this press release, as well as NIP Group’s strategic and operational plans, contain forward-looking statements. NIP Group may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about NIP Group’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIP Group’s growth strategies; its future business development, results of operations and financial condition; its ability to maintain and enhance the recognition and reputation of its brand; developments in the relevant governmental laws, regulations, policies toward NIP Group’s industry; and general economic and business conditions globally and in the countries or regions where NIP Group has operations; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIP Group’s filings with the SEC. All information provided in this press release is as of the date of this press release, and NIP Group undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

NIP Group Inc.
Investor Relations: [email protected] 
Public Relations: [email protected]